Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Juneyoung, Ahn"'
Autor:
Hye Sung Won, Juneyoung Ahn, Yongseon Kim, Jin Sung Kim, Jeong-Yoon Song, Hong-Kyu Kim, Jeeyeon Lee, Heung Kyu Park, Yong-Seok Kim
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background There is an increasing interest in HER2-low breast cancer with promising data from clinical trials using novel anti-HER2 antibody–drug conjugates. We explored the differences in clinicopathological characteristics and survival o
Externí odkaz:
https://doaj.org/article/3b273d13aaea45d092347e96b1a88b2e
Autor:
Yong Joon, Lee, Jee Ye, Kim, Seung Hyuck, Jeon, Heejin, Nam, Jae Hyung, Jung, Minwoo, Jeon, Eui-Soon, Kim, Soong June, Bae, Juneyoung, Ahn, Tae-Kyung, Yoo, Woo Young, Sun, Sung Gwe, Ahn, Joon, Jeong, Su-Hyung, Park, Woo Chan, Park, Seung Il, Kim, Eui-Cheol, Shin
Publikováno v:
Science immunology. 7(74)
Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune response in breast cancer, we examined the heterogen
Autor:
Yong Joon Lee, Jee Ye Kim, Seung Hyuck Jeon, Heejin Nam, Jae Hyung Jung, Minwoo Jeon, Eui-Soon Kim, Soong June Bae, Juneyoung Ahn, Tae-Kyung Yoo, Woo Young Sun, Sung Gwe Ahn, Joon Jeong, Su-Hyung Park, Woo Chan Park, Seung Il Kim, Eui-Cheol Shin
Publikováno v:
Science Immunology. 7
Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune response in breast cancer, we examined the heterogen
Publikováno v:
Cancer Research. 81:PS1-54
Introduction Incidence of microinvasive Breast cancer (DCISM) along with ductal carcinoma in situ is increasing due to mammographic screening. However, DCISM is not a common pathologic entity and surgical management of the axilla, overall treatment,
Publikováno v:
Cancer Research. 81:PS13-45
Purpose Pathological complete response (pCR) predicts improved survival in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). However, the prognosis of patients with non-pCR remains unclear. The aim of this study was to evaluate the ef
Autor:
Byung Joo Chae, Dahye Kim, Woo Chan Park, Kyungdo Han, Se Jeong Oh, Tae-Kyung Yoo, Juneyoung Ahn
Publikováno v:
Cancer Research. 80:P2-08
Background: Ductal carcinoma in situ (DCIS) patients are mostly diagnosed through cancer screening programs, suggesting that this population may have a healthy screenee effect of being more health-conscious, have lower comorbidity and belong to a hig
Autor:
Hassan, Alyami, Tae Kyung, Yoo, Jong Ho, Cheun, Han Byoel, Lee, Sung Mi, Jung, Jai Min, Ryu, Soong June, Bae, Joon, Jeong, Chang Ik, Yoon, Juneyoung, Ahn, Pill Sun, Paik, Min Kyung, Cho, Woo Chan, Park
Publikováno v:
Journal of Breast Cancer
Purpose Li-Fraumeni syndrome (LFS) is a rare autosomal cancer syndrome caused by a germline mutation in the TP53 gene. Breast cancer in LFS patients is of various subtypes; however, limited data are available on the clinicopathological features of th
Publikováno v:
Journal of Breast Cancer. 25:106
The aim of this study was to evaluate the radiological response rate patterns during neoadjuvant chemotherapy (NAC) in patients with breast cancer.Patients who underwent NAC with two specific chemotherapy regimens (doxorubicin with cyclophosphamide o
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 29(7)
Background: Hormone replacement therapy (HRT) increases the risk of breast cancer, but the association may vary according to patient factors. We investigated the association between HRT and breast cancer in a nationwide cohort with risk stratificatio
Autor:
Tae-Kyung Yoo, Byung Joo Chae, Sung Hun Kim, Juneyoung Ahn, Byung Joo Song, Bong Joo Kang, Woo Chan Park
Publikováno v:
Breast cancer research and treatment. 181(2)
The ACOSOG Z0011 trial demonstrated that axillary lymph node dissection (ALND) is unnecessary in select patients with cT1-2N0 tumors undergoing breast-conserving therapy with 1–2 positive sentinel lymph nodes (SLNs). However, patients with preopera